Hutchmed (china) (00013.HK) announced in conjunction with Innovent Bio (01801.HK) the new drug application for the combined therapy of Ayotux (fuquintinib) and Dabarshu (sintilimab injection) for the treatment of patients with advanced mismatch repair proficient endometrial cancer who have previously failed systemic antitumor therapy and are unsuitable for radical surgical or radiotherapy has been conditionally approved in china. Previously, this combined therapy was included in the priority review and breakthrough therapy designation by the National Medical Products Administration.